Hemoglobin infusion augments the tumor necrosis factor response to bacterial endotoxin (lipopolysaccharide) in mice.

OBJECTIVE To determine whether cell-free hemoglobin augments the inflammatory cascade, as detected by production of tumor necrosis factor (TNF) elicited by bacterial endotoxin (lipopolysaccharide [LPS]). DESIGN In vivo and ex vivo study, using a mouse model of sepsis. SETTING Animal research facility SUBJECTS Female Swiss Webster mice. INTERVENTIONS For the in vivo experiments, an LD50 dose (500 microg) of Escherichia coli LPS was injected intraperitoneally into mice. Cell-free crosslinked hemoglobin (60 mg/mouse) or saline was administered intravenously 10 hrs before or coincident with LPS. For the ex vivo experiments, hemoglobin (60 mg/mouse) or saline was administered intravenously to mice, and, 10 hrs later, hepatic Kupffer cells, peripheral blood mononuclear cells, or peritoneal macrophages were isolated. MEASUREMENTS AND MAIN RESULTS Intravenous infusion of hemoglobin either 10 hrs before or coincident with intraperitoneal LPS resulted in a peak of plasma TNF that was greater than in control mice administered LPS only. Cultured Kupffer cells, isolated from mice that had received hemoglobin in vivo 10 hrs before cell collection, produced more TNF in response to LPS in vitro than cells from normal mice. A trend toward greater TNF production in vitro by peripheral blood mononuclear cells obtained from hemoglobin-treated mice also was observed. Enhanced sensitivity to LPS was not observed with cultured peritoneal macrophages from mice that had received hemoglobin. CONCLUSIONS Intravenous hemoglobin increased the sensitivity of hepatic macrophages to subsequent stimulation by LPS. This effect may contribute to the increased mortality that we have observed in animals that have received both LPS and hemoglobin.

[1]  D. Su,et al.  Hemoglobin increases mortality from bacterial endotoxin , 1997, Infection and immunity.

[2]  R. Rabinovici,et al.  Liposome-encapsulated hemoglobin modulates lipopolysaccharide-induced tumor necrosis factor-alpha production in mice. , 1997, Critical care medicine.

[3]  R. Roth Hemoglobin Enhances the Binding of Bacterial Endotoxin to Human Endothelial Cells , 1996, Thrombosis and Haemostasis.

[4]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[5]  J. Langermans,et al.  Safety evaluation of a polymerized hemoglobin solution in a murine infection model. , 1996, The Journal of laboratory and clinical medicine.

[6]  M. Fink,et al.  Effect of human hemoglobin on systemic and regional hemodynamics in a porcine model of endotoxemic shock. , 1996, Critical care medicine.

[7]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[8]  J. Ogden,et al.  Haemoglobin‐Based Red Cell Substitutes: Current Status , 1995, Vox sanguinis.

[9]  A. Cross,et al.  The importance of a lipopolysaccharide-initiated, cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli. , 1995, The Journal of clinical investigation.

[10]  B. Schröppel,et al.  PROTECTIVE EFFECTS OF HYDROXYETHYL STARCH‐DEFEROXAMINE IN EARLY SEPSIS , 1995, Shock.

[11]  J. Jones Red blood cell substitutes: current status. , 1995, British journal of anaesthesia.

[12]  K. Burhop,et al.  THE EFFECTS OF DIASPIRIN CROSS-LINKED HEMOGLOBIN IN SEPSIS , 1995 .

[13]  Jan A. M. Langermans,et al.  Haemoglobin-based blood substitutes and infection , 1995, The Lancet.

[14]  D. Pepper,et al.  Haemoglobin-based blood substitutes and sepsis , 1995, The Lancet.

[15]  R. Roth,et al.  Human hemoglobin increases the biological activity of bacterial lipopolysaccharides in activation of Limulus amebocyte lysate and stimulation of tissue factor production by endothelial cells in vitro , 1994 .

[16]  R. Roth,et al.  Hemoglobin, a newly recognized lipopolysaccharide (LPS)-binding protein that enhances LPS biological activity. , 1994, The Journal of biological chemistry.

[17]  R. Roth Hemoglobin enhances the production of tissue factor by endothelial cells in response to bacterial endotoxin. , 1994, Blood.

[18]  E. Abraham Clinical sepsis trials. , 1994, Chest.

[19]  J. Bonaventura,et al.  Cell-free hemoglobin reverses the endotoxin-mediated hyporesponsivity of rat aortic rings to alpha-adrenergic agents. , 1994, Biochemical and biophysical research communications.

[20]  R. Roth,et al.  Production of modified crosslinked cell‐free hemoglobin for human use: the role of quantitative determination of endotoxin contamination , 1993, Transfusion.

[21]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[22]  J. Eaton,et al.  Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  W. Fiers,et al.  Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia , 1993, The Journal of experimental medicine.

[24]  K. Feingold,et al.  Role for monokines in the metabolic effects of endotoxin. Interferon-gamma restores responsiveness of C3H/HeJ mice in vivo. , 1992, The Journal of clinical investigation.

[25]  R. Bone,et al.  Sepsis syndrome. New insights into its pathogenesis and treatment. , 1991, Infectious disease clinics of North America.

[26]  P. Brandtzaeg,et al.  Current understanding of the pathogenesis of gram-negative shock. , 1991, Infectious disease clinics of North America.

[27]  J. Eaton,et al.  Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[28]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways , 1990 .

[29]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[30]  P. Brandtzaeg,et al.  Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response , 1989, The Journal of experimental medicine.

[31]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[32]  T. Ikejima,et al.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.

[33]  D. Remick,et al.  Acute in vivo effects of human recombinant tumor necrosis factor. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[34]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[35]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[36]  J. Berzofsky,et al.  The murine Kupffer cell. I. Characterization of the cell serving accessory function in antigen-specific T cell proliferation. , 1979, Journal of immunology.

[37]  I. Cohn,et al.  Enhancement of Escherichia coli infection and endotoxic activity by hemoglobin and ferric ammonium citrate. , 1970, Surgery.

[38]  H. Rogers,et al.  The effect of iron compounds on the virulence of Escherichia coli for guinea-pigs. , 1968, Immunology.

[39]  E. Hook,et al.  THE INFLUENCE OF HEMOLYSIS OR BLOOD LOSS ON SUSCEPTIBILITY TO INFECTION. , 1963, Journal of immunology.

[40]  C. W. Walter,et al.  Synergistic Toxicity of Gram‐negative Bacteria and Free Colloidal Hemoglobin , 1963, Annals of surgery.

[41]  K. Kaushansky,et al.  A new year greeting from a new editor , 1998, Blood.

[42]  N. Hsia,et al.  The toxicities of native and modified hemoglobins. , 1997, Free radical biology & medicine.

[43]  W. Alvord,et al.  Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. , 1995, The Journal of infectious diseases.

[44]  R. Winslow,et al.  Pilot-scale preparation of hemoglobin solutions. , 1994, Methods in enzymology.

[45]  I. Cohn,et al.  Hemoglobin as a bacterial virulence-enhancing factor in fluids produced in strangulation intestinal obstruction. , 1968, The American surgeon.